Navigation Links
PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
Date:7/27/2009

SOUTH PLAINFIELD, N.J., July 27 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 2 clinical trial of PTC299 in adult patients with neurofibromatosis type 2 (NF2), a rare genetic disorder that causes the development of non-malignant brain tumors. PTC299 is a novel, orally administered investigational new drug that is designed to selectively block tumor-related vascular endothelial growth factor (VEGF). With its novel mechanism of action, PTC299 has the potential to meet significant unmet medical need in NF2 and other conditions resulting from the overexpression of VEGF.

(Logo:http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

VEGF plays a critical role in the formation of new blood vessels or angiogenesis and its suppression has been shown to decrease tumor size and improve hearing in some patients with NF2. PTC299 selectively blocks the tumor-related production of VEGF, while sparing the physiological VEGF expression necessary to maintain the growth and function of normal blood vessels. Patients with NF2 typically develop tumors that compress the auditory nerves, often leading to deafness and problems with balance. If unchecked, NF2-related tumors may eventually damage other cranial nerves and the brainstem, and become life-threatening. Current standard treatments for NF2-related tumors include surgery and radiation therapy. However, a study conducted at Massachusetts General Hospital and recently published in the New England Journal of Medicine validates the potential of anti-angiogenesis therapies for NF2 patients.

"The development of PTC299 for the treatment of NF2 is noteworthy for patients, especially following our recent findings that an angiogenesis inhibitor improved hearing and led to tumor shrinkage in some patients," said Sco
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
2. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
3. Cell Therapeutics, Inc. Announces Exercise of Overallotment
4. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
5. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
7. Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
8. Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens
9. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
10. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
11. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Pensacola, FL (PRWEB) June 18, 2013 ... sleep/wake monitoring solutions for the global research community, announced ... Scientific Advisory Board. Dr. Matsudo is the Scientific Director ... do Sul (CELAFISCS), a Professor of Medicine at Gama ... Paulo Program, organized by the State Secretariat of Health ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Kitware ... today announces a new Fast-Track award from the U.S. ... design-analysis environment (IDAE) for the nuclear power industry. , ... for more than 30 years, but the United States’ ... remarkable gains in power plant utilization through improved refueling, ...
(Date:6/17/2013)... FL (PRWEB) June 17, 2013 As a ... are committed to finding a cure all for acne, rosacea, ... the AARS (Acne and Rosacea Society) has ... conditions, and helping to educate the public on treatment options. ... society by announcing their daily news updates via social networks ...
(Date:6/17/2013)... and BOSTON , June 17, 2013 ... set to reach $127 billion by 2018, accounting for nearly ... recently released Orphan Drug Report 2013 from ... needs in regard to this growing segment of the pharmaceutical ... database to include in-depth, fact-based orphan drug analysis with data ...
Breaking Biology Technology:Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board 2Kitware to Develop an Open-Source HPC Design-Analysis Environment for Nuclear Energy Research 2Acne and Rosacea Awareness Month: Probiotic Action Announces their Daily News Updates with Insight on the Most Common Skin Conditions 2Evaluate Launches Enhanced Orphan Drug Intelligence 2Evaluate Launches Enhanced Orphan Drug Intelligence 3
... in the Materials Science and Technology division of ... injection, detection and precession of spin accumulation in ... at temperatures up to 225 degrees Celsius. These ... in Si is viable as a basis for ...
... 5, 2011 Codexis, Inc. (NASDAQ: CDXS ) ... 31, 2011.   First Quarter Financial Highlights:Revenue: ... of $31.0 million, an increase of 21% from $25.7 million ... million increased 106% over the same time period driven by ...
... 2011 In parts of the world where dengue fever ... is a waste not only of time and money. It ... infection called chikungunya—its high fever, joint pain that can last ... of dengue. Recovery from the acute phase of the infection ...
Cached Biology Technology:NRL scientists achieve high temperature milestone in silicon spintronics 2NRL scientists achieve high temperature milestone in silicon spintronics 3Codexis Reports First Quarter 2011 Results 2Codexis Reports First Quarter 2011 Results 3Codexis Reports First Quarter 2011 Results 4Codexis Reports First Quarter 2011 Results 5Codexis Reports First Quarter 2011 Results 6Codexis Reports First Quarter 2011 Results 7SRI International and CTK Biotech Developing Low-Cost Diagnostic for Hard-to-Diagnose Chikungunya Virus 2SRI International and CTK Biotech Developing Low-Cost Diagnostic for Hard-to-Diagnose Chikungunya Virus 3
(Date:6/17/2013)... Research Foundation and Horizon Pharma further establish their commitment ... 2013 AGA-Horizon Pharma Fellow Abstract Prizes and the 2013 ... year, this competition continues to grow in popularity among ... basic and clinical research," said Nicholas F. LaRusso, MD, ... extremely proud of all that these fellows and students ...
(Date:6/17/2013)... A new study ... can be reversed with treatment. The study by researchers from ... McGill University and at Universit de Montral found that blocking ... mice with advanced Alzheimer,s disease (AD) recovers memory and cerebrovascular ... in May, also suggest an underlying mechanism of AD ...
(Date:6/16/2013)... triggered a similar marine ecosystem crisis to those witnessed ... according to research published today in Nature Geoscience ... of Newcastle, UK, Cologne, Frankfurt and GEOMAR-Kiel, confirms the ... marine ecosystem during the mid-Cretaceous greenhouse period. ... and duration of the temperature change.,Analysing the geochemistry and ...
Breaking Biology News(10 mins):Horizon Pharma Abstract Prizes recognize promising fellows and students 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2Global cooling as significant as global warming 2
... a specific mutation of the COX2 gene seems to ... increasing womens susceptibility to developing the disease. The ... confirmed by further studies, it might be possible to ... ibuprofen, which are used already for other conditions, to ...
... have found evidence that supports the theory that reproductive ... at the level of sperm cell motility. In a ... Society Interface, a team led by Michael Berns, an ... of biomedical engineering at the Beckman Laser Institute ...
... sequencing technology that can in one fell swoop decode 50 ... a research team led by University of Delaware scientists is ... switched on or off in rice--a crop vital to the ... which is supported by a $5.3-million grant from the National ...
Cached Biology News:Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 2Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 3Primate sperm competition: speed matters 2UD leads $5.3-million research project on rice epigenetics 2UD leads $5.3-million research project on rice epigenetics 3UD leads $5.3-million research project on rice epigenetics 4
iEMS Thermal Microplate Holder...
...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... oligonucleotides: PTOs are internucleotide modifications, ... backbone is replaced by a sulphur atom. ... degradation. PTOs are available as ... Oligonucleotides with thio-caps ...
Biology Products: